Article (Scientific journals)
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†
Cottereau, A.S.; Becker, S.; Broussais, F. et al.
2016In Annals of Oncology, 27, p. 719-724
Peer Reviewed verified by ORBi
 

Files


Full Text
Annals of oncology - Pronostic value of baseline total metabolic tumor... - 2016.pdf
Publisher postprint (167 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
FDG-PET/CT; metabolic volume; PTCL
Abstract :
[en] Background: Most peripheral T-cell lymphoma (PTCL) patients have a poor outcome and the identification of prognostic factors at diagnosis is needed. Patients and methods: The prognostic impact of total metabolic tumor volume (TMTV0), measured on baseline [18F] <br />2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography, was evaluated in a retrospective study including 108 PTCL patients (27 PTCL not otherwise specified, 43 angioimmunoblastic T-cell lymphomas and 38 anaplastic large-cell lymphomas). All received anthracycline-based chemotherapy. TMTV0 was computed with the 41% maximum standardized uptake value threshold method and an optimal cut-off point for binary outcomes was determined and compared with others prognostic factors. <br />Results: With a median follow-up of 23 months, 2-year progression-free survival (PFS) was 49% and 2-year overall survival (OS) was 67%. High TMTV0 was significantly associated with a worse prognosis. At 2 years, PFS was 26% in patients with a high TMTV0 (>230 cm3, n = 53) versus 71% for those with a low TMTV0, [P < 0.0001, hazard ratio (HR) = 4], whereas OS was 50% versus 80%, respectively, (P = 0.0005, HR = 3.1). In multivariate analysis, TMTV0 was the only significant independent parameter for both PFS and OS. TMTV0, combined with PIT, discriminated even better than TMTV0 alone, patients with an adverse outcome (TMTV0 >230 cm3 and PIT >1, n = 33,) from those with good prognosis (TMTV0 ≤230 cm3 and PIT ≤1, <br />n = 40): 19% versus 73% 2-year PFS (P < 0.0001) and 43% versus 81% 2-year OS, respectively (P = 0.0002). Thirty-one patients (other TMTV0–PIT combinations) had an intermediate outcome, 50% 2-year PFS and 68% 2-year OS. <br />Conclusion: TMTV0 appears as an independent predictor of PTCL outcome. Combined with PIT, it could identify different risk categories at diagnosis and warrants further validation as a prognostic marker.
Disciplines :
Hematology
Author, co-author :
Cottereau, A.S.
Becker, S.
Broussais, F.
Casasnovas, O.
Kanoun, S.
Roques, M.
Charrier, N.
Bertrand, S.
Delarue, R.
Bonnet, Christophe ;  Université de Liège > GIGA-R : Hématologie
Hustinx, Roland  ;  Université de Liège > Département des sciences cliniques > Médecine nucléaire
Gaulard, P.
de Leval, L.
Vera, P.
Itti, E.
Mounier, N.
Haioun, C.
Tilly, H.
Meignan, M.
More authors (9 more) Less
Language :
English
Title :
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†
Publication date :
April 2016
Journal title :
Annals of Oncology
ISSN :
0923-7534
eISSN :
1569-8041
Publisher :
Oxford University Press, London, United Kingdom
Volume :
27
Pages :
719-724
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 05 February 2017

Statistics


Number of views
123 (6 by ULiège)
Number of downloads
230 (0 by ULiège)

Scopus citations®
 
80
Scopus citations®
without self-citations
64
OpenCitations
 
71

Bibliography


Similar publications



Contact ORBi